Outcome of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli: Impact of microbiological determinants

Journal of Infection

Volumn 67, Issue 1, 2013, Pages 27-34

  Rodríguez Baño, Jesús ^a,b   Mingorance, Jesús ^c   Fernández Romero, Natalia ^c   Serrano, Lara ^a   López Cerero, Lorena ^a   Pascual, Alvaro ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antimicrobial resistance; Bloodstream infections; Escherichia coli; Extended spectrum beta lactamases; Mortality; Phylogroups; Virulence factors

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; VIRULENCE FACTOR;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; GENE IDENTIFICATION; HUMAN; ISOELECTRIC FOCUSING; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHYLOGENY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK;

AGED; BACTEREMIA; BETA-LACTAMASES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; SPAIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRULENCE FACTORS;

EID: 84878353106     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.04.006     Document Type: Article

References (42)

1. Johnson J.R., Russo T.A. Molecular epidemiology of extraintestinal pathogenic (uropathogenic) Escherichia coli. Int J Med Microbiol 2005, 295:383-404.
2. Wiles T.J., Kulesus R.R., Mulvey M.A. Origins and virulence mechanisms of uropathogenic Escherichia coli. Exp Mol Pathol 2008, 85:11-19.
3. Maslow J.N., Mulligan M.E., Adams K.S., Justus J.C., Arbeit R.D. Bacterial adhesins and host factors: role in the development and outcome of Escherichia coli bacteremia. Clin Infect Dis 1993, 17:89-97.
4. Hekker T.A.M., Groeneveld A.B.J., Simoons-Smit A.M., de Man P., Connell H., MacLaren D.M. Role of bacterial virulence factors and host factors in the outcome of Escherichia coli bacteraemia. Eur J Clin Microbiol Infect Dis 2000, 19:312-316.
5. Martínez J.A., Soto S., Fabrega A., Almela M., Mensa J., Soriano A., et al. Relationship of phylogenetic background, biofilm production, and time to detection of growth in blood culture vials with clinical variables and prognosis associated with Escherichia coli bacteremia. J Clin Microbiol 2006, 44:1468-1474.
6. Jauréguy F., Carbonelle E., Bonacorsi S., Clec'h C., Casassus P., Bingen E., et al. Host and bacterial determinants of initial severity and outcome of Escherichia coli sepsis. Clin Microbiol Infect 2007, 13:854-862.
7. Lefort A., Panhard X., Clermont O., Woerther P.L., Branger C., Mentré F., et al. Host factors and portal of entry outweigh bacterial determinants to predict the severity of Escherichia coli bacteremia. J Clin Microbiol 2011, 49:777-783.
8. Rodríguez-Baño J., Pascual A. Clinical significance of extended-spectrum β-lactamases. Expert Rev Anti Infect Ther 2008, 6:671-683.
9. Courpon-Claudinon A., Lefort A., Pahnard X., Clermont O., Dornic Q., Fantin B., et al. Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence molecular epidemiology, and clinical features. Clin Microbiol Infect 2011, 17:557-565.
10. Rodríguez-Baño J., Mingorance J., Fernández-Romero N., Serrano L., López-Cerero L., Pascual A. Virulence profiles of bacteremic extended-spectrum β-lactamase-producing Escherichia coli: association with epidemiological and clinical features. PLoS One 2012, 7:e44238. The ESBL-REIPI Group.
11. van der Bij A.K., Peirano G., Goessens W.H., van der Vorm E.R., van Westreenen M., Pitout J.D. Clinical and molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli causing bacteremia in the Rotterdam Area, Netherlands. Antimicrob Agents Chemother 2011, 55:3576-3578.
12. Rodríguez-Baño J., Picón E., Gijón P., Hernández J.R., Ruíz M., Peña C., et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010, 50:40-48.
13. Rodríguez-Baño J., Picón E., Gijón P., Hernández J.R., Cisneros J.M., Peña C., et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. J Clin Microbiol 2010, 48:1726-1731.
14. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
15. Paterson D.L., Ko W.C., Von Gottberg A., Mohapatra S., Casellas J.M., Goossens H., et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann Intern Med 2004, 140:26-32.
16. Clinical and Laboratory Standard Institute Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement 2010, CLSI, Wayne, PA, CLSI document M100-S20.
17. Clermont O., Lavollay M., Vimont S., Deschamps C., Forestier C., Branger C., et al. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother 2008, 61:1024-1028.
18. Clermont O., Dhanji H., Upton M., Gibreel T., Fox A., Boyd D., et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 2009, 64:274-277.
19. Clermont O., Bonacorsi S., Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 2000, 66:4555-4558.
20. Johnson J.R., Stell A.L. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J Infect Dis 2000, 181:261-272.
21. Le Bouguenec C., Archambaud M., Labigne A. Rapid and specific detection of the pap, afa, and sfa adhesin-encoding operons in uropathogenic Escherichia coli strains by polymerase chain reaction. J Clin Microbiol 1993, 30:1189-1193.
22. Karkkainen U.M., Kauppinen J., Ikaheimo R., Katila M.L., Siitonen A. Rapid and specific detection of three different G adhesin classes of P-fimbriae in uropathogenic Escherichia coli by polymerase chain reaction. J Microbiol Methods 1999, 34:23-29.
23. Blanco M., Blanco J.E., Alonso M.P., Mora A., Balsalobre C., Muñoa F., et al. Detection of pap, sfa and afa adhesin-encoding operons in uropathogenic Escherichia coli strains: relationship with expression of adhesins and production of toxins. Res Microbiol 1997, 148:745-755.
24. Yamamoto S., Teai A., Yuri K., Kurazono H., Takeda Y., Yoshida O. Detection of urovirulence factors in Escherichia coli by multiplex polymerase chain reaction. FEMS Immunol Med Microbiol 1995, 12:85-90.
25. Ananias M., Yano T. Serogroups and virulence genotypes of Escherichia coli isolated from patients with sepsis. Braz J Med Biol Res 2008, 41:877-883.
26. Nakano M., Yamamoto S., Terai A., Ogawa O., Makino S.I., Hayashi H., et al. Structural and sequence diversity of the pathogenicity island of uropathogenic Escherichia coli which encodes the USP protein. FEMS Microbiol Lett 2001, 205:71-76.
27. Russo T.A., Carlino U.B., Johnson J.R. Identification of a new iron-regulated virulence gene, ireA, in an extraintestinal pathogenic isolate of Escherichia coli. Infect Immun 2001, 69:6209-6216.
28. Girardeau J.P., Lalioui L., Said A.M., De Champs C., Le Bouguénec C. Extended virulence genotype of pathogenic Escherichia coli isolates carrying the afa-8 operon: evidence of similarities between isolates from humans and animals with extraintestinal infections. J Clin Microbiol 2003, 41:218-226.
29. Bidet P., Metais A., Mahjoub-Messai F., Durand L., Dehem M., Aujard Y., et al. Detection and identification by PCR of a highly virulent phylogenetic subgroup among extraintestinal pathogenic Escherichia coli B2 strains. Appl Environ Microbiol 2007, 72:2373-2377.
30. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: definitions for sepsis and organ failure and guidelines for use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874.
31. Soriano A., Martínez J.A., Mensa J. Reply to Lustberg and to Poraith and Brooks. Clin Infect Dis 2008, 46:1484-1485.
32. Blanco J., Mora A., Mamani R., López C., Blanco M., Dahbi G., et al. National survey of Escherichia coli causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4-B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain. J Antimicrob Chemother 2011, 66:2011-2021.
33. Pitout J.D.D., Gregson D.B., Campbell L., Laupland K.B. Molecular characteristics of extended-Spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother 2009, 53:2846-2851.
34. Chung H.C., Lai C.H., Lin J.N., Huang C.K., Liang S.H., Chen W.F., et al. Bacteremia caused by extended-spectrum-β-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrob Agents Chemother 2012, 56:618-622.
35. Sannes M.R., Kuskowski M.A., Owens K., Gajewski A., Johnson J.R. Virulence factor profiles and phylogenetic background of Escherichia coli isolates from veterans with bacteremia and uninfected control subjects. J Infect Dis 2004, 190:2121-2128.
36. Johnson J.R., Kuskowski M.A., O'Bryan T.O., Maslow J.N. Epidemiological correlates of virulence genotype and phylogenetic background among Escherichia coli blood isolates from adults with diverse-source bacteremia. J Infect Dis 2002, 185:1439-1447.
37. Wang M.C., Tseng C.C., Chen C.Y., Wu J.J., Huang J.J. The role of bacterial virulence and host factors in patients with Escherichia coli bacteremia who have acute cholangitis or upper urinary tract infection. Clin Infect Dis 2002, 35:1161-1166.
38. Moreno E., Planells I., Prats G., Planes A.M., Moreno G., Andreu A. Comparative study of Escherichia coli virulence determinants in strains causing bacteremia versus strains causing pyelonephritis and other sources of bacteremia. Diagn Microbiol Infect Dis 2005, 53:93-99.
39. Bingen E., Bonacorsi S., Brahimi N., Denamur E., Elion J. Virulence patterns of Escherichia coli K1 strains associated with neonatal meningitis. J Clin Microbiol 1997, 35:2981-2982.
40. Wang S., Niu C., Shi Z., Xia Y., Yaqoob M., Dai J., et al. Effects of ibeA deletion on virulence and biofilm formation of avian pathogenic Escherichia coli. Infect Immun 2011, 79:279-287.
41. Johnson J.R., Nicolas-Chanoine M.H., DebRoy C., Castanheira M., Robicsek A., Hansen G., et al. Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967-2009. Emerg Infect Dis 2012, 18:598-607.
42. Johnson J.R., Porter S.B., Zhanel G., Kuskowski M.A., Denamurd E. Virulence of Escherichia coli clinical isolates in a murine sepsis model in relation to sequence type ST131 status, fluoroquinolone resistance, and virulence genotype. Infect Immun 2012, 80:1554-1562.